Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma

Published:2011-01-25 Issue: Volume: Page:no-no
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:

Author:

Benedict Ágnes,Figlin Robert A.,Sandström Per,Harmenberg Ulrika,Ullén Anders,Charbonneau Claudie,Sandin Rickard,Remák Edit,Hariharan Subramanian,Négrier Sylvie

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2010.09957.x/fullpdf

Reference36 articles.

1. National Institute for Clinical Excellence (NICE) Technology appraisal guidance 169: sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma http://www.nice.org.uk/guidance/TA169/Guidance/pdf/English

2. The Swedish Pharmaceutical Benefits Board (LFN) Guidelines for companies http://www.tlv.se/Upload/English/Guidelines-for-Companies.pdf

3. Pharmaceutical Benefits Board General guidelines for economic evaluation from the Pharmaceutical Benefits Board http://www.ispor.org/PEguidelines/countrydet.asp?c=21&t=1

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment;Nature Reviews Urology;2023-03-16

2. Socio‐economic burden of disease: Survivorship costs for renal cell carcinoma;European Journal of Cancer Care;2022-03-15

3. Cost-Effectiveness of Immunotherapy Treatments for Renal Cell Carcinoma: A Systematic Review;Kidney Cancer;2021-03-23

4. Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not;European Urology Open Science;2020-12

5. An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy;Journal of Medical Economics;2020-11-05